Source: bioopticsworld.co
Author: staff

Pharmaceuticals company, Abbott (Des Plaines, IL), announced an agreement with GSK to develop an automated molecular diagnostic test, also based on RT-PCR technology, to screen non-small cell lung cancer (NSCLC) tumors for expression of the MAGE-A3 antigen. GSK’s MAGE-A3 ASCI (antigen specific cancer immunotherapy) candidate is currently being evaluated as an adjuvant treatment in resected NSCLC in the Phase III clinical study MAGRIT, the largest lung cancer treatment study ever conducted.

Fast, accurate influenza testing
The GSK-Enigma partnership aims for joint development of the Enigma ML (mini laboratory) PCR platform to deliver fully-automated results from swab samples in less than 60 minutes at the point of care–to the same accuracy standards as reference laboratories. Thus, patients can be tested for specific influenza subtypes and quickly receive appropriate treatment. Operators of the Enigma ML system will not require specialist training.

A trial involving working prototypes of the ML system with front line health care providers across Europe is planned for Q4 2009. Launch of Enigma ML is anticipated in early 2011, subject to successful clinical trials and regulatory approval.

Cancer immunotherapy
Under terms of the GSK-Abbott agreement, the partners will develop and commercialize an RT-PCR test–designed to detect MAGE A3–for use on the Abbott m2000 automated instrument system.

“This is an exciting collaboration with a leading company in cancer immunotherapy research,” said Stafford O’Kelly, head of Abbott’s molecular diagnostics business. “The agreement is indicative of our focus on personalized medicine and developing analytical molecular tools to identify patients most likely to benefit from important pharmacogenomic therapies.”

Currently, there are no nucleic acid based tests approved by the U.S. Food and Drug Administration for use in identifying patients who may derive treatment benefits from targeted non-small cell lung cancer therapies.

“Lung cancer is the biggest cancer killer globally,” said Vincent Brichard, M.D., Ph.D., vice president and head of Immunotherapeutics, GSK. “Through this partnership we aim to make MAGE-A3 testing of lung tumors available in standard pathology labs around the world. This means patients globally could be able to find out if they are eligible and can potentially benefit from targeted cancer treatment against this antigen, such as GSK’s MAGE-A3 candidate ASCI.” MAGE-A3 is a tumor-specific antigen that is expressed in non-small cell lung cancer and a wide variety of other cancers (including melanoma, head and neck cancer, and bladder cancer), but not in normal cells. To be eligible to receive GSK’s MAGE A3 ASCI, patients must have MAGE-A3 expressing NSCLC tumors.

GSK says its ASCIs represent a novel class of medicines designed to train the immune system to recognize and eliminate cancer cells in a highly specific manner. They combine tumor antigens, delivered as purified recombinant proteins, and GSK’s proprietary Adjuvant Systems, which are specific combinations of immunostimulating compounds selected to increase the anti-tumor immune response. ASCIs are being investigated in the clinic to support their use to reduce the risk of tumor recurrence following surgery, or to impact tumor growth in an early metastatic setting. The highly specific mode of action of GSK’s ASCIs allows development of diagnostic tools to aid in selecting patients eligible for the treatment, depending on the expression of the tumor antigens.

MAGE-A3 protein has been in-licensed by GSK from the Ludwig Institute for Cancer Research, the largest international academic institute dedicated to understanding and controlling cancer. MAGE-A3 ASCI is an investigational compound and it is not approved for use in any indication in any country at this time.

Print Friendly, PDF & Email